Silver sulfadiazine

Silver sulfadiazine
Clinical data
Trade namesSilvadene
Other names(4-Amino-N-2-pyrimidinylbenzenesulfonamidato-NN,01)-silver, sulfadiazine silver, silver (I) sulfadiazine, 4-amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
AHFS/Drugs.comMonograph
MedlinePlusa682598
Pregnancy
category
  • B (not recommended in late pregnancy)
Routes of
administration		Topical
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability<1% (silver), 10% (sulfadiazine)
Protein bindingHigh (silver)
Excretion2/3 kidney (sulfadiazine)
Identifiers
IUPAC name
  • Silver [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.040.743
Chemical and physical data
FormulaC10H9AgN4O2S
Molar mass357.14 g·mol−1
3D model (JSmol)
Melting point285 °C (545 °F)
SMILES
  • [Ag+].O=S(=O)([N-]c1ncccn1)c2ccc(N)cc2
InChI
  • InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1 Y
  • Key:UEJSSZHHYBHCEL-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

Silver sulfadiazine, sold under the brand Silvadene among others, is a topical antibiotic used in partial thickness and full thickness burns to prevent infection.[1] Tentative evidence has found other antibiotics to be more effective, and therefore it is no longer generally recommended for second-degree (partial-thickness) burns, but is still widely used to protect third-degree (full-thickness) burns.[2][3]

Common side effects include itching and pain at the site of use.[4] Other side effects include low white blood cell levels, allergic reactions, bluish grey discoloration of the skin, red blood cell breakdown, or liver inflammation.[4] Caution should be used in those allergic to other sulfonamides.[4] It should not be used in pregnant women who are close to delivery.[4] It is not recommended for use in children less than two months of age.[4]

Silver sulfadiazine was discovered in the 1960s.[5] It is on the World Health Organization's List of Essential Medicines.[6] It is available as a generic medication.[4] In 2022, it was the 279th most commonly prescribed medication in the United States, with more than 700,000 prescriptions.[7][8]

  1. ^ Singer AJ, Taira BR, Lee CC (2013). "Thermal Burns". In Marx J, Walls R, Hockberger R (eds.). Rosen's Emergency Medicine - Concepts and Clinical Practice. Elsevier Health Sciences. p. 814. ISBN 978-1455749874. Archived from the original on 13 September 2016.
  2. ^ Wasiak J, Cleland H, Campbell F, Spinks A (March 2013). "Dressings for superficial and partial thickness burns". The Cochrane Database of Systematic Reviews. 2013 (3): CD002106. doi:10.1002/14651858.CD002106.pub4. hdl:10072/58266. PMC 7065523. PMID 23543513. It is impossible to draw firm and confident conclusions about the effectiveness of specific dressings, however silver sulphadiazine was consistently associated with poorer healing outcomes than biosynthetic, silicon-coated and silver dressings whilst hydrogel-treated burns had better healing outcomes than those treated with usual care.
  3. ^ Heyneman A, Hoeksema H, Vandekerckhove D, Pirayesh A, Monstrey S (November 2016). "The role of silver sulphadiazine in the conservative treatment of partial thickness burn wounds: A systematic review". Burns. 42 (7): 1377–1386. doi:10.1016/j.burns.2016.03.029. hdl:1854/LU-8507323. PMID 27126813.
  4. ^ a b c d e f "Silver Sulfadiazine". Drugs.com. American Society of Health-System Pharmacists. 1 June 2008. Archived from the original on 20 September 2016. Retrieved 30 August 2016.
  5. ^ Chung DH, Colon NC, Herndon DN (2012). "Burns". In Coran AG, Caldamone A, Adzick NS, Krummel TM, Laberge J, Shamberger R (eds.). Pediatric Surgery (7 ed.). Elsevier Health Sciences. p. 369. ISBN 978-0323091619. Archived from the original on 13 September 2016.
  6. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  7. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  8. ^ "Silver Sulfadiazine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.